NCT05580003View on ClinicalTrials.gov

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

September 15, 2023

Study Completion Date

September 15, 2023

Conditions
Healthy
Interventions
DRUG

PF-07817883

Oral suspension or solid oral formulation(s)

DRUG

Placebo

Placebo suspension

DRUG

Midazolam

midazolam oral solution

DRUG

Moxifloxacin

Moxifloxacin 400 mg tablet

Trial Locations (2)

06511

New Haven Clinical Research Unit, New Haven

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05580003 - A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People | Biotech Hunter | Biotech Hunter